The study will be conducted in the Netherlands at four sites and Telormedix anticipates that a total of 21 patients to 30.. The trial is a Phase I / II, open-label, multicenter, dose escalation study, which will consist of three parts. During the first part of the study the safety and maximum tolerated dose in patients with non – muscle invasive bladder cancer who have undergone a complete transurethral resection are tested.

The requirements are comprehensive, yet flexible enough and they provide needed safeguards for patients without unnecessary regulation.Together with the potential for great benefit, products from the human body, such as HCT / Ps derived risks of transmission of communicable diseases especially if donors are not properly shielded and tested. Continue reading